文献速递骨软组织肉瘤与黑色素瘤

高危黏液样脂肪肉瘤新辅助化疗:意大利(ISG)、西班牙(GEIS)、法国(FSG)和波兰肉瘤组(PSG)随机试验扩展队列结果

Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).
PubMed 文献 · J Clin Oncol · 2024-01-17

该随机试验扩展队列纳入101例局限期高危黏液样脂肪肉瘤患者,比较组学定制方案(HT,曲贝替定)与标准蒽环类+异环磷酰胺(AI)方案。HT组45例,S组56例,中位随访66个月。60个月无病生存率两组分别为0.86和0.73(HR 0.60,95%CI 0.24-1.46),总生存率分别为0.88和0.90(HR 1.20,95%CI 0.37-3.93)。贝叶斯分析显示HT非劣效于S,曲贝替定可作为AI的替代选择。

要点

  • 高危黏液样脂肪肉瘤扩展队列显示组学定制方案(曲贝替定)非劣效于标准AI方案。
  • 60个月无病生存率HT组0.86 vs S组0.73,HR 0.60(95%CI 0.24-1.46),未达统计学显著。
  • 60个月总生存率HT组0.88 vs S组0.90,HR 1.20(95%CI 0.37-3.93),无显著差异。

核心结论

  • 在局限期高危黏液样脂肪肉瘤中,当考虑新辅助治疗时,曲贝替定可能是标准AI方案的替代选择。

研究设计与样本

  • 随机试验扩展队列,纳入101例局限期高危黏液样脂肪肉瘤患者,随机分配至组学定制方案组(HT,45例)或标准蒽环类+异环磷酰胺方案组(S,56例)。
  • 主要终点为无病生存期(DFS),次要终点为总生存期(OS),采用非劣效贝叶斯设计,若真实风险比(HR)>1.25的后验概率<5%则判定HT非劣效于S。

主要发现

  • 中位随访66个月(IQR 37-89),中位肿瘤大小107 mm(IQR 84-143),HT组106 mm(IQR 75-135),S组108 mm(IQR 86-150)。
  • 60个月DFS概率HT组0.86 vs S组0.73(HR 0.60,95%CI 0.24-1.46;log-rank P=0.26)。
  • 60个月OS概率HT组0.88 vs S组0.90(HR 1.20,95%CI 0.37-3.93;log-rank P=0.77)。
  • DFS的HR>1.25后验概率为4.93%,满足贝叶斯监测界值<5%,证实曲贝替定非劣效于AI。

临床怎么用

  • 作者认为,在局限期高危黏液样脂肪肉瘤考虑新辅助治疗时,曲贝替定可能是标准AI方案的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A randomized trial was conducted to compare neoadjuvant standard (S) anthracycline + ifosfamide (AI) regimen with histology-tailored (HT) regimen in selected localized high-risk soft tissue sarcoma (STS). The results of the trial demonstrated the superiority of S in all STS histologies except for high-grade myxoid liposarcoma (HG-MLPS) where S and HT appeared to be equivalent. To further evaluate the noninferiority of HT compared with S, the HG-MLPS cohort was expanded. PATIENTS AND METHODS: Patients had localized high-grade (cellular component >5%; size ≥5 cm; deeply seated) MLPS of extremities or trunk wall. The primary end point was disease-free survival (DFS). The secondary end point was overall survival (OS). The trial used a noninferiority Bayesian design, wherein HT would be considered not inferior to S if the posterior probability of the true hazard ratio (HR) being >1.25 was <5%. RESULTS: From May 2011 to June 2020, 101 patients with HG-MLPS were randomly assigned, 45 to the HT arm and 56 to the S arm. The median follow-up was 66 months (IQR, 37-89). Median size was 107 mm (IQR, 84-143), 106 mm (IQR, 75-135) in the HT arm and 108 mm (IQR, 86-150) in the S arm. At 60 months, the DFS and OS probabilities were 0.86 and 0.73 (HR, 0.60 [95% CI, 0.24 to 1.46]; log-rank P = .26 for DFS) and 0.88 and 0.90 (HR, 1.20 [95% CI, 0.37 to 3.93]; log-rank P = .77 for OS) in the HT and S arms, respectively. The posterior probability of HR being >1.25 for DFS met the Bayesian monitoring cutoff of <5% (4.93%). This result confirmed the noninferiority of trabectedin to AI suggested in the original study cohort. CONCLUSION: Trabectedin may be an alternative to standard AI in HG-MLPS of the extremities or trunk when neoadjuvant treatment is a consideration.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). J Clin Oncol. 2024. PMID: 38232337. doi:10.1200/JCO.23.00908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。